What is the 13F Pro Quality Score for IMNN?

13F Pro ranks Imunon, Inc. (IMNN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IMNN's current score at https://13fpro.ai/research/IMNN (free sign-up required for the full ranking).

Where does 13F Pro source IMNN data?

All Imunon, Inc. fundamentals and ownership data come directly from SEC EDGAR. Imunon, Inc. files with the SEC under CIK 749647. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IMNN in?

Imunon, Inc. (IMNN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IMNN research updated on 13F Pro?

IMNN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Imunon, Inc.(IMNN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 749647 IMNN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.5M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

IMNN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Imunon, Inc. (IMNN), a Healthcare sector company. IMNN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.5m in revenue. Based on the latest XBRL financial filings (Q1 2026), Imunon, Inc. reports net income of $-4.2M, free cash flow of $-4.0M. Top institutional holders of IMNN by reported 13-F value include ARMISTICE CAPITAL,, Riverview Capital Advisers,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. IMNN trades on the Nasdaq exchange and files with the SEC under CIK 749647. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMNN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Imunon, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-4.2M

Free Cash Flow

Q1 2026

$-4.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY19 $500.0KFY20 $500.0KFY21 $500.0KFY25 —

Net Income

+30.2% YoY

$-14.5MFY 2025

FY19 $-16.9MFY20 $-21.5MFY21 $-20.8MFY25 $-14.5M

Operating Income

+30.3% YoY

$-14.7MFY 2025

FY19 $-20.6MFY20 $-18.5MFY21 $-21.0MFY25 $-14.7M

EPS (Diluted)

$-6.83FY 2025

FY19 —FY20 —FY21 —FY25 $-6.83

Total Assets

-83.4% YoY

$12.3MFY 2025

FY19 $38.3MFY20 $37.5MFY21 $74.0MFY25 $12.3M

Total Debt

—FY 2025

FY19 $9.8MFY20 $5.1MFY21 —FY25 —

Op. Cash Flow

+14.3% YoY

$-13.9MFY 2025

FY19 $-20.3MFY20 $-15.6MFY21 $-16.2MFY25 $-13.9M

Metric	FY 2025	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	—	$500.0K +0.0%	$500.0K +0.0%	$500.0K +0.0%	$500.0K +0.0%	$500.0K
Net Income	$-14.5M +30.2%	$-20.8M +3.3%	$-21.5M -27.5%	$-16.9M -41.8%	$-11.9M +41.8%	$-20.4M
Operating Income	$-14.7M +30.3%	$-21.0M -13.6%	$-18.5M +10.1%	$-20.6M +2.4%	$-21.1M -14.1%	$-18.5M
EPS (Diluted)	$-6.83	—	—	—	—	—
Total Assets	$12.3M -83.4%	$74.0M +97.3%	$37.5M -2.0%	$38.3M -18.3%	$46.9M -1.4%	$47.5M
Total Debt	—	—	$5.1M -48.5%	$9.8M +4.1%	$9.4M	—
Operating Cash Flow	$-13.9M +14.3%	$-16.2M -3.9%	$-15.6M +22.9%	$-20.3M -187.7%	$-7.0M +57.7%	$-16.6M

AI Insight: IMNN Financial Trends

Imunon remains pre-revenue with quarterly losses stabilizing around $3–4M, but equity volatility and negative cash flow persist.

• Net income and operating income losses narrowed from $5M in Q2 2024 to $3–4M by Q2 2025, suggesting improved cost control.

• Operating cash outflow averaged $4M per quarter in Q4 2025 and Q1 2026, consistent with prior periods; no revenue generation.

⚠ Equity swung from $0M (Q1 2025) to $7M (Q4 2025) to $3M (Q1 2026), signaling balance-sheet instability amid ongoing losses.

⚠ Company remains fully pre-clinical with zero revenue; cash burn sustainability and path to clinical trials remain unclear.

AI Insight: IMNN Ratio Trends

Insufficient data: all ratio fields are blank across the entire period; unable to assess operational or financial trends.

• No quantitative data available to evaluate margin trends, profitability, or return metrics across Q2 2024–Q1 2026.

⚠ Complete absence of reported ratios suggests either pre-revenue stage, data gaps, or reporting delays requiring clarification.

Get alerted when IMNN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Imunon, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IMNN

ARMISTICE CAPITAL, LLC
$1.0M348,330 sh
Riverview Capital Advisers, LLC
$247.8K34,364 sh
VANGUARD CAPITAL MANAGEMENT LLC
$141.3K48,056 sh
GEODE CAPITAL MANAGEMENT, LLC
$97.6K33,211 sh
VANGUARD FIDUCIARY TRUST CO
$39.0K13,269 sh
BlackRock, Inc.
$13.1K4,464 sh
WELLS FARGO & COMPANY/MN
$9.8K3,342 sh
MORGAN STANLEY
$8.9K3,035 sh
Tower Research Capital LLC (TRC)
$5.5K1,866 sh
SBI Securities Co., Ltd.
$3.0K1,027 sh

Fund	Value	Shares
ARMISTICE CAPITAL, LLC	$1.0M	348,330
Riverview Capital Advisers, LLC	$247.8K	34,364
VANGUARD CAPITAL MANAGEMENT LLC	$141.3K	48,056
GEODE CAPITAL MANAGEMENT, LLC	$97.6K	33,211
VANGUARD FIDUCIARY TRUST CO	$39.0K	13,269
BlackRock, Inc.	$13.1K	4,464
WELLS FARGO & COMPANY/MN	$9.8K	3,342
MORGAN STANLEY	$8.9K	3,035
Tower Research Capital LLC (TRC)	$5.5K	1,866
SBI Securities Co., Ltd.	$3.0K	1,027

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IMNN on your watchlist

Track score changes the day Imunon, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IMNN a good stock to buy?

13F Pro's AI-powered analysis of Imunon, Inc. (IMNN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMNN are available on the IMNN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IMNN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMNN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Imunon, Inc.'s investment landscape.